Proteomics Is Estimated To Witness High Growth Owing To Increasing Application In Disease Diagnosis And Drug Development
The Proteomics Market is estimated to be valued at US$ 36.8 Bn in 2023 and is expected to exhibit a CAGR Of 14.% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview
Proteomics is the large-scale study of proteins, particularly their structures and functions. Proteomics techniques such as mass spectrometry, chromatography, and protein microarrays allow for rapid analysis of a proteome at a given stage of cell development or disease process. Proteomics is used for protein analysis, pharmaceutical development and drug discovery and disease diagnosis and treatment monitoring.
Market Dynamics
The proteomics market is expected to witness significant growth over the forecast period owing to increasing application in disease diagnosis and drug development. Proteomics aids in understanding pathophysiology at molecular level and identification of potential disease biomarker. This enables early detection and diagnosis of diseases including cancer. Furthermore, proteomics helps in facilitating drug discovery and development process by aiding target identification, validation and facilitating efficacy and safety analysis. Drug companies are increasingly adopting proteomics to streamline drug R&D process.
The market is witnessing growth owing to increasing incidences of chronic diseases globally and growing investments by pharmaceutical and biotechnology companies in proteomics. In addition, technological advancements in mass spectrometry instruments and increasing integration of omics technologies such as genomics and metabolomics with proteomics is expected to augment market growth over the forecast period.
SWOT Analysis
Strength: Proteomics allows analysis of thousands of proteins simultaneously which helps understand functioning of biological systems at a molecular level. It enables identification of disease biomarkers and therapeutic drug targets. Growing research activities across pharma and biotech industries rely on proteomics approaches.
Weakness: Proteomics experiments involve complex workflows and computationally intensive data analysis which requires specialized expertise. High costs involved in proteomics instruments, consumables and data analysis software limits its application.
Opportunity: Rising focus on personalized medicine provides opportunities for proteomics to study genetic variations and individual disease states. Growing biopharmaceutical industry adoption for drug discovery and development expanded scope. Increasing genomic research activities complement proteomics for deeper biological insights.
Threats: Stringent regulatory landscape for proteomics-based diagnostics delays commercialization. Lack of standardization across different proteomics platforms limits data reproducibility and validation. Intense competition from alternative omics technologies like metabolomics.
Key Takeaways
The Global Proteomics Market Demand is expected to witness high growth, exhibiting CAGR of 14% over the forecast period, due to increasing focus on personalized medicine and drug discovery efforts. Proteomics applications in biomarker identification and therapeutic target discovery are driving market demand.
Regional analysis North America dominated the global proteomics market in 2023 and is expected to remain the largest market during the forecast period. This is attributed to presence of major players, growing biomedical research funding and robust pharma industry in the region. Asia Pacific region is anticipated to exhibit fastest growth in the proteomics market owing to increasing government focus on healthcare reforms and establishing specialized research centers.
Key players operating in the proteomics market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), and Waters Corporation (US). Thermo Fisher offers comprehensive portfolio of mass spectrometers, sample preparation solutions, software and informatics solutions catering to proteomics research. Danaher is another prominent player offering protein characterization and purification instruments and consumables through its subsidiaries like Beckman Coulter, Inc.
Get more insights on this topic :
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian